By Jonathan Gardner | BioPharma Dive
Published July 17, 2026
In a significant blow to its respiratory pipeline, British pharmaceutical giant GSK announced this week that it will cease all clinical development of camlipixant. The decision follows a series of underwhelming results in Phase 3 clinical trials, marking the third time a drug candidate in the P2X3 receptor antagonist class has failed to clear the high bar of regulatory and clinical success. For GSK, the move represents the termination of a high-profile asset acquired during a period of aggressive portfolio expansion, leaving the field of refractory chronic cough (RCC) treatment in a state of renewed uncertainty.
The Main Facts: A Pipeline Purge
The clinical failure of camlipixant was confirmed after a review of top-line data from the drug’s late-stage development program. GSK, which brought the asset into its fold via the $2 billion acquisition of Bellus Health in 2023, had high hopes that the selective P2X3 antagonist would provide relief to the millions suffering from persistent, treatment-resistant coughs.
However, the late-stage data proved to be inconsistent. While one study showed a statistically significant reduction in 24-hour cough frequency compared to a placebo at the 50 mg twice-daily dose, the second pivotal trial failed to replicate these results. Furthermore, the 25 mg twice-daily dosage failed to meet primary endpoints in both studies. Perhaps more concerning to regulatory analysts was the failure of the program to meet key secondary endpoints, signaling a lack of robust clinical efficacy that would be necessary to secure approval from the FDA or the European Medicines Agency (EMA).
Chronology of a Failed Asset
The road to this week’s announcement has been long and marked by both promise and peril. The history of camlipixant (formerly BLU-5937) illustrates the volatile nature of drug development in the respiratory space.
- 2020: The drug initially stumbled in a Phase 2 trial, failing to meet the primary endpoint for cough reduction, which dampened investor enthusiasm at the time.
- 2021–2022: Despite the initial setback, researchers pivoted, refining the dosage and patient selection criteria. A subsequent mid-stage study yielded much more promising data, demonstrating that the drug could indeed dampen the hypersensitivity of the cough reflex.
- 2023: GSK moved to acquire Bellus Health. The deal was widely seen as a strategic play to solidify GSK’s leadership in respiratory medicine, viewing camlipixant as a "best-in-class" potential therapy.
- 2024–2025: GSK launched an ambitious global Phase 3 program, aiming to differentiate camlipixant from Merck’s Gefapixant, which had already faced significant regulatory hurdles.
- July 2026: Following the receipt of the mixed Phase 3 results, GSK executives made the difficult decision to terminate the program, officially closing the book on the asset.
Supporting Data: Why the Trials Failed
The failure of camlipixant is not an isolated incident but rather the latest in a string of challenges for P2X3 antagonists. These drugs are designed to target specific nerve receptors in the airway that, when over-sensitized, trigger the urge to cough.
In the late-stage trials, GSK evaluated multiple dosing regimens. The 50 mg dose was intended to provide the "Goldilocks" effect—enough power to stop the cough, but not so much that it causes the hallmark side effect of these drugs: dysgeusia, or the loss/distortion of taste.
Data revealed that while the 50 mg dose achieved a significant reduction in cough frequency in the first study, the second trial’s failure created a lack of reproducibility. Statistical analysis of the secondary endpoints—which included quality-of-life assessments and patient-reported outcomes—also fell short. Without clear evidence that the drug improves the patient’s day-to-day existence, the path to market was effectively blocked. The failure of the lower 25 mg dose further complicated the picture, suggesting that there was no "safe" window that could guarantee both efficacy and a manageable safety profile across a diverse patient population.
Official Responses and Market Reaction
GSK has maintained a posture of "disciplined capital allocation." In a statement, the company noted that while the results were disappointing, the decision to stop development allows the firm to reallocate resources toward more promising areas of its pipeline.
Market analysts, however, have been quick to weigh in. Michael Leuchten, an analyst at Jefferies, provided a pragmatic assessment in a note to clients. "The failure is disappointing, but it is not a material setback to the GSK equity story," Leuchten wrote. He pointed out that investors have largely moved on, focusing instead on GSK’s oncology portfolio.
However, Leuchten did not let management off the hook entirely. He noted that the Bellus acquisition occurred under the current leadership team, including Chief Commercial Officer Luke Miels and R&D head Tony Wood. Their involvement in the acquisition process means the failure is a stain on the current R&D strategy, even if the financial impact is relatively contained.
Conversely, the market reacted with enthusiasm toward smaller players in the space. Trevi Therapeutics, which is developing its own treatment for cough, saw its shares climb as much as 16% in the wake of the news. The sentiment is clear: as a massive, potential competitor exits the field, the remaining players have a clearer path to capture market share.
Implications for the Chronic Cough Landscape
The failure of camlipixant sends a clear message to the pharmaceutical industry: the P2X3 pathway is proving far more difficult to tame than initially anticipated. With three major drugs in the class failing to gain significant traction or regulatory approval, companies are being forced to rethink their approach to chronic cough.
1. The "Open Field" Opportunity
For companies like Trevi Therapeutics, the void left by GSK is significant. Trevi’s lead candidate, Haduvio, is an opioid-based therapy that has been repurposed to address the sensory hypersensitivity associated with coughs in patients with idiopathic pulmonary fibrosis (IPF) and other refractory conditions. Analysts at Leerink Partners have described this as an "open field opportunity," suggesting that if Trevi can demonstrate safety and efficacy where others have failed, they could become the dominant player in a market that remains heavily underserved.
2. A Shift in R&D Focus
For GSK, this failure underscores the importance of a diversified portfolio. As Leuchten noted, the company’s long-term value is increasingly tied to its oncology assets and vaccine business. The "cough medicine" market, while large, is plagued by complex, multi-factorial causes that are difficult to treat with a single-molecule approach. We may see GSK pivot away from niche respiratory conditions toward broader immunological or oncology-based treatments where they have already established a proven track record.
3. The Regulatory Bar
Regulators have shown extreme caution regarding P2X3 antagonists, particularly due to the persistent issue of taste distortion. Because chronic cough is not a terminal illness, the safety-to-efficacy ratio required for approval is extraordinarily high. The failure of camlipixant serves as a warning to other developers: any drug that compromises a basic sensory function like taste must show overwhelming efficacy in clinical trials to be considered for approval.
Conclusion: The Path Forward
The termination of the camlipixant program is a somber reminder of the "fail fast" reality of modern biopharma. While the loss of a late-stage asset is never easy, GSK’s willingness to walk away from a project that lacked the necessary clinical robustness is arguably a sign of a mature, disciplined research organization.
As the industry looks forward, the focus will undoubtedly shift to next-generation therapies. Whether the future lies in repurposed opioids, novel neuro-modulators, or gene-based therapies remains to be seen. For the millions of patients living with the debilitating effects of chronic, refractory cough, the wait for a safe, effective, and tolerable treatment continues. For GSK, the goal remains the same: delivering value through scientific innovation, even if the path to that innovation is occasionally blocked by the harsh realities of the clinic.
